Sugi Predict

Sugi Predict / Compounds / SCHEMBL3633700

SCHEMBL3633700

SCHEMBL3633700

CCCNc1cc(F)c(F)cc1N

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.34
▸ PRSS1 P07477 4/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ AOC1 P19801 1/20 0.33
▸ PIM1 P11309 1/20 0.33
▸ TLR8 Q9NR97 1/20 0.33
▸ TRPA1 O75762 2/20 0.32
▸ CISD1 Q9NZ45 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ GFER P55789 1/20 0.32
▸ PLEC Q15149 1/20 0.32
▸ MAPK14 Q16539 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30657518 1.00 MAPT (0.34) MAPTPRSS1IDO1AOC1PIM1
SCHEMBL21872454 0.87 AR (0.34) MAPTPRSS1IDO1AOC1TLR8
SCHEMBL979910 0.83 KDM4E (0.44) MAPTAOC1PIM1LMNAKDM4E
SCHEMBL30657533 0.83 KDM4E (0.44) MAPTAOC1PIM1LMNAKDM4E
SCHEMBL18893379 0.81 IDO1 (0.36) MAPTIDO1TRPA1CISD1ALDH1A1
SCHEMBL14934074 0.80 AR (0.36) TRPA1LMNA
SCHEMBL3630498 0.78 TSHR (0.41) MAPTPRSS1IDO1AOC1TLR8
SCHEMBL15240240 0.78 TLR8 (0.47) MAPTPRSS1PIM1TLR8CISD1
SCHEMBL21318229 0.78 AR (0.43) MAPTIDO1TRPA1ALDH1A1HTT
SCHEMBL3631150 0.77 ALDH1A1 (0.42) IDO1TLR8TRPA1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2026-04-09 — — US disclosed
US-12458642-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-11-04 — — US disclosed
EP-4311577-A2 METALLOENZYME INHIBITOR COMPOUNDS Ji Xing Pharmaceuticals Hong Kong Limited (HK) 2024-01-31 — — EP disclosed
EP-3562487-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2023-11-29 — — EP disclosed
EP-3562487-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2023-11-29 — — EP disclosed
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) 2021-10-21 — — US disclosed
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) 2021-10-21 — — US disclosed
US-11040034-B2 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. (US) 2021-06-22 — — US disclosed
US-11040034-B2 Metalloenzyme inhibitor compounds PHASEBIO PHARMACEUTICALS, INC. (US) 2021-06-22 — — US disclosed
EP-3562487-A2 METALLOENZYME INHIBITOR COMPOUNDS Selenity Therapeutics (Bermuda), Ltd. (BM) 2019-11-06 — — EP disclosed
US-20190008861-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2019-01-10 — — US disclosed
US-10085984-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-10-02 — — US disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 — — US disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 — — US disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 — — US disclosed
WO-2018125800-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-07-05 — — WO disclosed
WO-2018125800-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) 2018-07-05 — — WO disclosed
EP-2146969-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Novartis Ag (CH) 2010-01-27 — — EP disclosed
US-20090105266-A1 Organic compounds NOVARTIS AG (CH) 2009-04-23 — — US disclosed
WO-2008128968-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 NOVARTIS AG (CH) 2008-10-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105266-A1 Organic compounds SLCO2B1, SLCO1B1, SLCO1B3 MAPT 995/4885PRSS1 2208/4885IDO1 340/4885
US-12458642-B2 Metalloenzyme inhibitor compounds CYP11B2, CYP11B1, HSD11B2 MAPT 2593/4885PRSS1 345/4885IDO1 935/4885
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH MAPT 2388/4885PRSS1 284/4885IDO1 1842/4885
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CPN1, TPP1, DPP4 MAPT 2173/4885PRSS1 444/4885IDO1 678/4885
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH MAPT 2388/4885PRSS1 284/4885IDO1 1842/4885
US-11040034-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH MAPT 2388/4885PRSS1 284/4885IDO1 1842/4885
US-20190008861-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH MAPT 2388/4885PRSS1 284/4885IDO1 1842/4885
US-10085984-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH MAPT 2388/4885PRSS1 284/4885IDO1 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.